Suppression of glucose production by GLP-1 independent of islet hormones: A novel extrapancreatic effect

American Journal of Physiology - Endocrinology and Metabolism

Volumn 285, Issue 4 48-4, 2003, Pages

  Prigeon, Ronald L ^a,b   Quddusi, Shaista ^a   Paty, Breay ^a   D'Alessio, David A ^a,c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b BALTIMORE VA MEDICAL CENTER   (United States)

^c UNIVERSITY OF CINCINNATI   (United States)

Author keywords

Gastrointestinal hormone; Glucose production; Glucose tolerance; Incretin; Pancreatic clamp

Indexed keywords

C PEPTIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN;

ADULT; ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; GLUCAGON RELEASE; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HORMONE ACTION; HORMONE BLOOD LEVEL; HORMONE RELEASE; HUMAN; HUMAN EXPERIMENT; INSULIN BLOOD LEVEL; INSULIN RELEASE; MALE; NORMAL HUMAN; PANCREAS ISLET CELL; PRIORITY JOURNAL; STEADY STATE;

EID: 0141615898     PISSN: 01931849     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpendo.00024.2003     Document Type: Article

References (51)

1. Adkins BA, Myers SR, Hendrick GK, Stevenson RW, Williams PE, and Cherrington AD. Importance of the route of intravenous glucose delivery to hepatic glucose balance in the conscious dog. J Clin Invest 79: 557-565, 1987.
2. Ahren B, Larsson H, and Holst JJ. Effects of glucagon-like peptide-1 on islet function and insulin sensitivity in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 82: 473-478, 1997.
3. Balkan B and Li X. Portal GLP-1 administration in rats augments the insulin response to glucose via neuronal mechanisms. Am J Physiol Regul Integr Comp Physiol 279: R1449-R1454, 2000.
4. Blackmore PF, Mojsov S, Exton JH, and Habener JF. Absence of insulinotropic glucagon-like peptide-1(7-37) receptors on isolated rat liver hepatocytes. FEBS Lett 283: 7-10, 1991.
5. Bullock BP, Heller RS, and Habener JF. Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology 137: 2968-2978, 1996.
6. Burcelin R, Da Costa A, Drucker D, and Thorens B. Glucose competence of the hepatoportal vein sensor requires the presence of an activated glucagon-like peptide-1 receptor. Diabetes 50: 1720-1728, 2001.
7. Butler PC, Caumo A, Zerman A, O'Brien PC, Cobelli C, and Rizza RA. Methods for assessment of the rate of onset and offset of insulin action during nonsteady state in humans. Am J Physiol Endocrinol Metab 264: E548-E560, 1993.
8. Cherrington AD, Stevenson RW, Steiner KE, Davis MA, Myers SR, Adkins BA, Abumrad NN, and Williams PE. Insulin, glucagon, and glucose as regulators of hepatic glucose uptake and production in vivo. Diabetes Metab Rev 3: 307-332, 1987.
9. Creutzfeldt W and Nauck M. Gut hormones and diabetes mellitus. Diabetes Metab Rev 8: 149-177, 1992.
10. D'Alessio DA and Ensinck JW. The regulation of islet hormone secretion by GLP-1 in humans. In: The Insulinotropic Hormone Glucagon-like Peptide 1, edited by Fehmann HC and Goeke B. Basel, Switzerland: Karger, 1996.
11. D'Alessio DA, Kahn SE, Leusner CR, and Ensinck JW. Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal. J Clin Invest 93: 2263-2266, 1994.
12. D'Alessio DA, Prigeon RL, and Ensinck JW. Enteral enhancement of glucose disposition by both insulin-dependent and insulin-independent processes: a physiologic role of Glucagon-like peptide 1. Diabetes 44: 1433-1437, 1995.
13. 2-terminus in type II diabetic patients and in healthy subjects. Diabetes 44: 1126-1131, 1995.
14. Dillon JS, Tanizawa Y, Wheeler MB, Leng XH, Ligon BB, Rabin DU, Yoo-Warren H, Permutt MA, and Boyd AE III. Cloning and functional expression of the human glucagon-like peptide-1 (GLP-1) receptor. Endocrinology 133: 1907-1910, 1993.
15. Egan JM, Meneilly GS, Habener JF, and Elahi D. Glucagon-like Peptide-1 augments insulin-mediated glucose uptake in the obese state. J Clin Endocrinol Metab 87: 3768-3773, 2002.
16. Egan JM, Montrose-Rafizadeh C, Wang Y, Bernier M, and Roth J. Glucagon-like peptide 1 (7-36)amide enhances insulin-stimulated glucosemetabolism in 3T3-LI adipocytes: one of several potential extrapancreatic sites of GLP-1 action. Endocrinology 135: 2070-2075, 1994.
17. Ensinck JW, Shepard C, Dudl R, and Williams R. Use of benzamidine as a proteolytic inhibitor in the radioimmunoassay of glucagon in plasma. J Clin Endocrinol Metab 35: 463-468, 1971.
18. Felber JP, Thiebaud D, Maeder E, J, Jequier E, Hendler R, and DeFronzo RA. Effect of somatostatin-induced insulinopenia on glucose oxidation in man. Diabetologia 25: 325-330, 1983.
19. Ferrannini E, Bjorkman O, Reichard GA Jr, Pilo A, Olsson M, Wahren J, and DeFronzo RA. The disposal of an oral glucose load in healthy subjects: a quantitative study. Diabetes 34: 580-588, 1985.
20. Gutniak M, Orskov C, Holst J, Ahren B, and Efendic S. Antidiabetogenic effect of glucagon-like peptide-1(7-36) amide in normal subjects and patients with diabetes mellitus. N Engl J Med 326: 1316-1322, 1992.
21. Hansen BF, Jensen P, Nepper-Christensen E, and Skjolstrup B. Effects of glucagon-like peptide-1 (7-36)amide on insulin stimulated rat skeletal muscle glucose transport. Acta Diabetol 35: 101-103, 1998.
22. Hvidberg A, Nielsen MT, Hilsted J, Orskov C, and Holst JJ. Effect of glucagon-like peptide-1(proglucagon 78-107 amide) on hepatic glucose production in healthy man. Metabolism 43: 104-108, 1994.
23. Katz H, Butler P, Homan M, Zerman A, Caumo A, Cobelli C, and Rizza R. Hepatic and extrahepatic insulin action in humans: measurement in the absence of non-steady-state error. Am J Physiol Endocrinol Metab 264: E561-E566, 1993.
24. Krentz AJ, Boyle PJ, Macdonald LM, and Schade DS. Octreotide: a long-acting inhibitor of endogenous hormone secretion for human metabolic investigations. Metabolism 43: 24-31, 1994.
25. Kreymann B, Ghatei MA, Williams G, and Bloom SR. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 2: 1300-1303, 1987.
26. Larsson H, Holst JJ, and Ahren B. Glucagon-like peptide-1 reduces hepatic glucose production indirectly through insulin and glucagon in humans. Acta Physiol Scand 160: 413-422, 1997.
27. Lopez-Delgado MI, Morales M, Villanueva-Penacarrillo ML, Malaisse WJ, and Valverde I. Effects of glucagon-like peptide 1 on the kinetics of glycogen synthase a in hepatocytes from normal and diabetic rats. Endocrinology 139: 2811-2817, 1998.
28. McIntyre N, Holdsworth CD, and Turner DS. Intestinal factors in the control of insulin secretion. J Clin Endocrinol Metab 25: 1317-1324, 1965.
29. Meneilly GS, McIntosh CH, Pederson RA, Habener JF, Gingerich R, Egan JM, and Elahi D. Glucagon-like peptide-1 (7-37) augments insulin-mediated glucose uptake in elderly patients with diabetes. J Gerontol A Biol Sci Med Sci 56: M681-M685, 2001.
30. Meneilly GS, McIntosh CH, Pederson RA, Habener JF, Gingerich R, Egan JM, Finegood DT, and Elahi D. Effect of glucagon-like peptide 1 on non-insulin-mediated glucose uptake in the elderly patient with diabetes. Diabetes Care 24: 1951-1956, 2001.
31. Muller MJ, Moring J, and Seitz HJ. Regulation of hepatic glucose output by glucose in vivo. Metabolism 37: 55-60, 1988.
32. Nakabayashi H, Nishizawa M, Nakagawa A, Takeda R, and Niijima A. Vagal hepatopancreatic reflex effect evoked by intraportal appearance of tGLP-1. Am J Physiol Endocrinol Metab 271: E808-E813, 1996.
33. Orskov C, Rabenhoj L, Wettergren A, Kofod H, and Holst JJ. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide in humans. Diabetes 43: 535-539, 1994.
34. Orskov L, Holst JJ, Moller N, Alberti KGMM, and Schmitz O. GLP-1 does not acutely affect insulin sensitivity in healthy man. Diabetologia 39: 1227-1232, 1996.
35. Perley MJ and Kipnis DM. Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic subjects. J Clin Invest 46: 1954-1962, 1967.
36. Prigeon RL, D'Alessio DA, and Porte D Jr. A precise method for assay of tritiated glucose (Abstract). J Investig Med 46: 146A, 1998.
37. Prigeon RL, Vicini P, Cobelli C, Laschansky EC, D'Alessio DA. Glucagon-like peptide 1 does not alter insulin-dependent glucose uptake in humans (Abstract). J Investig Med 45: 147A, 1997.
38. Ryan AS, Egan JM, Habener JF, and Elahi D. Insulinotropic hormone glucagon-like peptide-1-(7-37) appears not to augment insulin-mediated glucose uptake in young men during euglycemia. J Clin Endocrinol Metab 83: 2399-2404, 1998.
39. Shalev A, Ninnis R, and Keller U. Effects of glucagon-like peptide 1 (7-36 amide) on glucose kinetics during somatostatin-induced suppression of insulin secretion in healthy men. Horm Res 49: 221-225, 1998.
40. Steele RWJ, DeBodo RC, Altszuler N, Kiang SP, and Bjerknes C. Measurement of size and turnover rate of body glucose pool by the isotope dilution method. Am J Physiol 187: 15-24, 1956.
41. Thorens B. Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1. Proc Natl Acad Sci USA 89: 8641-8645, 1992.
42. Toft-Nielsen M, Madsbad S, and Holst JJ. The effect of glucagon-like peptide 1 (GLP-1) on glucose elimination in healthy subjects depends on the pancreatic glucoregulatory hormones. Diabetes 45: 552-556, 1996.
43. Vella A, Shah P, Basu R, Basu A, Camilleri M, Schwenk FW, Holst JJ, and Rizza RA. Effect of glucagon-like peptide-1(7-36)-amide on initial splanchnic glucose uptake and insulin action in humans with type 1 diabetes. Diabetes 50: 565-572, 2001.
44. Vella A, Shah P, Basu R, Basu A, Holst JJ, and Rizza RA. Effect of glucagon-like peptide 1(7-36) amide on glucose effectiveness and insulin action in people with type 2 diabetes. Diabetes 49: 611-617, 2000.
45. Villanueva-Penacarrillo ML, Alcantara AI, Clemente F, Delgado E, and Valverde I. Potent glycogenic effect of GLP-1(7-36) amide in rat skeletal muscle. Diabetologia 37: 1163-1166, 1994.
46. Wei Y and Mojsov S. Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences. FEBS Lett 358: 219-224, 1995.
47. Weir GC, Mojsov S, Hendrick GK, and Habener JF- Glucagonlike peptide I (7-37) actions on endocrine pancreas. Diabetes 38: 338-342, 1989.
48. Wheeler MB, Lu M, Dillon JS, Leng X-H, Chen C, and Boyd AE. Functional expression of the rat glucagon-like peptide-1 receptor, evidence for coupling to both adenyl cyclase and phospholipase-C. Endocrinology 133: 57-62, 1993.
49. Willms B, Werner J, Holst JJ, Orskov C, Creutzfeldt W, and Nauck MA. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients. J Clin Endocrinol Metab 81: 327-332, 1996.
50. Weltering H. A Fortran package for generalized, cross-validatory spline smoothing and differentiation. Adv Eng Software 8: 104-107, 1986.
51. Zaharko D and Beck L. Studies of a simplified plasma insulin immunoassay using cellulose powder. Diabetes 17: 444-457, 1968.